Biotech company Seneca Biopharma, Inc. reported its financial results for the year ended December 31, 2020.
The year saw the company entering into a definitive Merger Agreement with private company Leading BioSciences, Inc. , which specializes in developing novel therapeutics to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
Net loss for 2020 came in at -$16.3 million, or -$1.17 per share, compared to a loss of -$8.4 million, or -$3.80 per share on a post-reverse stock-split basis, for the year-ago period. The 2020 widening of net loss was largely attributed to an increase in G&A, and a non-cash expense of $5.6 million related to the January 2020 warrant inducement offering.
Seneca’s offerings resulted in net proceeds of over $14.7 million in the year.
PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 48 cases where PALI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, 31 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PALI as a result. In 92 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PALI turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 40 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for PALI moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PALI entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.761) is normal, around the industry mean (3.037). P/E Ratio (1.892) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds
Industry Biotechnology